Strides Pharma Science Ltd

Strides Pharma Science demonstrates fluctuating financial performance. While sales have shown consistent growth, profit margins have been volatile. The company experienced net losses in 2022, 2023 and 2024 before recovering significantly in 2025. This inconsistency raises questions about the sustainability of its profitability. While revenue expansion is a positive sign, the instability in earnings needs consideration.

Strides Pharma Science's capital efficiency metrics raise concerns. The Return on Capital Employed (ROCE) and Return on Equity (ROE) are relatively low. ROCE fluctuated and was negative in 2023. ROE remained below 2% for the majority of the period, indicating that shareholder funds are not generating high returns. This suggests potential inefficiencies in how the company is utilizing its capital.

Strides Pharma Science's financial health presents a mixed picture. While the company has reduced its borrowings, it still carries a significant amount of debt. The interest coverage ratio, calculated using operating profit, has been volatile, influenced by fluctuating operating profits. The company's dividend payout has been inconsistent, with no payout in some years.

Strides Pharma Science's operational efficiency, as indicated by its working capital management, shows some challenges. The cash conversion cycle has been relatively high, indicating a longer time to convert investments in inventory and receivables into cash. Debtor days and inventory days have been extended, suggesting potential issues with collecting payments and managing inventory effectively.

Strides Pharma Science exhibits volatility in its segment performance. The quarterly results show significant fluctuations in both sales and profit growth. This variability indicates potential challenges in maintaining consistent financial performance across different segments or markets.

Strides Pharma Science's operations expose it to foreign exchange and interest rate risks. As the company operates internationally, fluctuations in exchange rates can impact its revenue and profitability. Additionally, changes in interest rates can affect the cost of its borrowings.

The available data does not suggest any significant accounting quality red flags for Strides Pharma Science. The financial statements appear to be consistent and transparent.